Novogene Future Growth
Future criteria checks 3/6
Novogene is forecast to grow earnings and revenue by 20.9% and 17.8% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be 9.4% in 3 years.
Key information
20.9%
Earnings growth rate
20.7%
EPS growth rate
Life Sciences earnings growth | 27.4% |
Revenue growth rate | 17.8% |
Future return on equity | 9.4% |
Analyst coverage | Low |
Last updated | 12 May 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,245 | 308 | N/A | 431 | 3 |
12/31/2025 | 2,766 | 259 | N/A | 496 | 4 |
12/31/2024 | 2,332 | 212 | N/A | 276 | 4 |
6/30/2024 | 2,069 | 181 | 85 | 256 | N/A |
3/31/2024 | 2,030 | 183 | 97 | 251 | N/A |
12/31/2023 | 2,002 | 178 | 217 | 334 | N/A |
9/30/2023 | 1,990 | 190 | 171 | 280 | N/A |
6/30/2023 | 2,006 | 196 | 170 | 319 | N/A |
3/31/2023 | 1,980 | 181 | 278 | 465 | N/A |
12/31/2022 | 1,926 | 177 | 87 | 304 | N/A |
9/30/2022 | 1,955 | 209 | 180 | 398 | N/A |
6/30/2022 | 1,914 | 200 | 222 | 386 | N/A |
3/31/2022 | 1,888 | 211 | 122 | 247 | N/A |
12/31/2021 | 1,866 | 225 | 181 | 293 | N/A |
9/30/2021 | 1,812 | 218 | 235 | 340 | N/A |
6/30/2021 | 1,707 | 193 | 316 | 413 | N/A |
3/31/2021 | 1,633 | 132 | 406 | 518 | N/A |
12/31/2020 | 1,490 | 37 | 250 | 342 | N/A |
9/30/2020 | 1,437 | -10 | -98 | 18 | N/A |
6/30/2020 | 1,550 | 9 | -196 | -63 | N/A |
3/31/2020 | 1,472 | 37 | -351 | -214 | N/A |
12/31/2019 | 1,535 | 114 | -87 | 85 | N/A |
9/30/2019 | 1,377 | 107 | -57 | 101 | N/A |
6/30/2019 | 1,219 | 100 | -26 | 117 | N/A |
3/31/2019 | 1,137 | 99 | 22 | 134 | N/A |
12/31/2018 | 1,054 | 97 | 70 | 151 | N/A |
12/31/2017 | 739 | 81 | N/A | 55 | N/A |
12/31/2016 | 458 | 39 | N/A | 95 | N/A |
12/31/2015 | 310 | 25 | N/A | 143 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688315's forecast earnings growth (20.9% per year) is above the savings rate (2.9%).
Earnings vs Market: 688315's earnings (20.9% per year) are forecast to grow slower than the CN market (22% per year).
High Growth Earnings: 688315's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688315's revenue (17.8% per year) is forecast to grow faster than the CN market (13.5% per year).
High Growth Revenue: 688315's revenue (17.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688315's Return on Equity is forecast to be low in 3 years time (9.4%).